Stay updated on Idasanutlin Combo Therapy in AML Clinical Trial
Sign up to get notified when there's something new on the Idasanutlin Combo Therapy in AML Clinical Trial page.

Latest updates to the Idasanutlin Combo Therapy in AML Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe clinical trial record for idasanutlin in newly diagnosed AML is displayed, with study design, eligibility, locations, outcome measures, and record documents. It reports that the trial was terminated after Phase 1 and that the planned Phase 2 was not initiated.SummaryDifference97%

- Check14 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology across its content.SummaryDifference1%

- Check28 days agoChange DetectedThe ClinicalTrials.gov footer revision changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check49 days agoChange DetectedThe page now shows a 403 Forbidden error page instead of the study content, with boilerplate HTML and a 403 title, indicating an access issue when attempting to view the study entry.SummaryDifference0.5%

Stay in the know with updates to Idasanutlin Combo Therapy in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Idasanutlin Combo Therapy in AML Clinical Trial page.